Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab ... Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old ...

After its approval in 2018, Libtayo made solid annual sales gains from $348 million in 2020 to $578 million two years later. In 2022, Regeneron paid its partner Sanofi $900 million for full rights ...

In a surprise announcement, Regeneron began a dividend at $0.88/share. A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Currently, the flagship of Regeneron's oncology franchise is Libtayo (cemiplimab-rwlc), which is an anti-PD-1 monoclonal antibody that is approved for the treatment of several types of cancer.

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors.

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply agreement supports the evaluation of Immuneering’s ...

Its skin cancer drug, Libtayo, brought in sales of $366.9 million, above estimates of $333.5 million. Regeneron bought the global rights to the cancer drug from partner Sanofi in 2022. The company ...

Meanwhile, Regeneron is also looking to diversify its revenue base to reduce its dependence on Eylea for top-line growth and build an oncology franchise, which currently comprises Libtayo.

SNY pays REGN a royalty on such sales. Regeneron records global net product sales of Libtayo and pays Sanofi a royalty on such sales. Total Libtayo sales came in at $366.9 million, up 50% year ...

The quarter saw Regeneron grow its revenue by 10% year ... Of its remaining product sales, standouts included cancer drug Libtayo, with a robust 50% gain to $367 million. The company's ...

Down 50% With a 5.9% Dividend Yield, Here's Why This Dirt Cheap Value Stock Is Worth Buying in February Want to Make More Passive Income? These 2 Dividend Stocks Offer Yields Above 6%. Want ...